Pre-clinical dose-ranging efficacy, pharmacokinetics, tissue biodistribution, and toxicity of a targeted contrast agent for MRI of amyloid deposition in Alzheimer’s disease

In these preclinical studies, we describe ADx-001, an Aβ-targeted liposomal macrocyclic gadolinium (Gd) imaging agent, for MRI of amyloid plaques. The targeting moiety is a novel lipid-PEG conjugated styryl-pyrimidine. An MRI-based contrast agent such as ADx-001 is attractive because of the lack of...

Descripción completa

Detalles Bibliográficos
Autores principales: Badachhape, Andrew A., Working, Peter K., Srivastava, Mayank, Bhandari, Prajwal, Stupin, Igor V., Devkota, Laxman, Tanifum, Eric A., Annapragada, Ananth V., Ghaghada, Ketan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527957/
https://www.ncbi.nlm.nih.gov/pubmed/32999398
http://dx.doi.org/10.1038/s41598-020-73233-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527957/
https://www.ncbi.nlm.nih.gov/pubmed/32999398
http://dx.doi.org/10.1038/s41598-020-73233-7

Ejemplares similares